Oramed Pharmaceuticals
ORMP
23 hedge funds and large institutions have $15.3M invested in Oramed Pharmaceuticals in 2014 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 5 closing their positions.
181% more call options, than puts
Call options by funds: $236K | Put options by funds: $84K
160% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 5
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
53% more funds holding
Funds holding: 15 → 23 (+8)
12% more capital invested
Capital invested by funds: $13.6M → $15.3M (+$1.68M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCI
Columbus Circle Investors
|
+$755K |
| 2 |
GIM
Greylin Investment Management
Orange,
Virginia
|
+$560K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$410K |
| 4 |
HSBC Holdings
London,
United Kingdom
|
+$253K |
| 5 |
TAM
Tocqueville Asset Management
New York
|
+$253K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TAM
Telluride Asset Management
Wayzata,
Minnesota
|
-$299K |
| 2 |
HCM
Highlander Capital Management
Short Hills,
New Jersey
|
-$15.4K |
| 3 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
-$15K |
| 4 |
FNYS
First New York Securities
New York
|
-$11K |
| 5 |
ASN
Advisory Services Network
Atlanta,
Georgia
|
-$4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FNYS
26
First New York Securities
New York
| – | -$11K | -736 | Closed |
|
|
ASN
27
Advisory Services Network
Atlanta,
Georgia
| – | -$4K | -285 | Closed |
|
28
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| – | +$709 | +42 | New |
|
ORMP Hedge Fund Activity: Q1 2014 in Review
23 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q1 2014, worth a combined $15.3M — up 12% from $13.6M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new ORMP positions and 5 closed out — a net gain of 8 holders — while 4 added to existing stakes and 2 trimmed.
The largest buyer was Columbus Circle Investors, opening a new position worth an estimated $755K. The largest seller was Telluride Asset Management, exiting entirely with an estimated $299K sold.
- 23 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q1 2014, up from 15 in Q4 2013.
- Funds reported $15.3M of Oramed Pharmaceuticals stock for Q1 2014, up 12% quarter-over-quarter.
- 13 funds opened new Oramed Pharmaceuticals positions in Q1 2014 and 5 closed out, a net change of +8 holders.
- The largest Oramed Pharmaceuticals buyer in Q1 2014 was Columbus Circle Investors, an estimated $755K added.
- The largest Oramed Pharmaceuticals seller in Q1 2014 was Telluride Asset Management, an estimated $299K sold.
Based on aggregated 13F filings for Q1 2014.